Get the Stockscreener App
8.75
1.74%
0.15
Pre-market:
8.75
Fulcrum Therapeutics Inc stock is traded at $8.75, with a volume of 659.10K.
It is up +1.74% in the last 24 hours and down -4.89% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$8.60
Open:
$8.59
24h Volume:
659.10K
Relative Volume:
1.22
Market Cap:
$473.30M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-5.538
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-5.10%
1M Performance:
-4.89%
6M Performance:
+127.27%
1Y Performance:
+176.90%
1-Day Range:
$8.42
$9.15
1-Week Range:
$8.29
$10.11
52-Week Range:
$2.315
$10.11
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.75 | 465.19M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Can Fulcrum Therapeutics Inc. stock resist sector downturnsMarket Weekly Review & Verified Entry Point Signals - newser.com
What is Leerink Partnrs' Estimate for FULC FY2025 Earnings? - MarketBeat
FY2025 EPS Forecast for Fulcrum Therapeutics Cut by Analyst - MarketBeat
FY2025 EPS Estimate for Fulcrum Therapeutics Cut by Analyst - MarketBeat
Why Fulcrum Therapeutics Inc. stock is in analyst buy zone2025 Short Interest & Fast Gaining Stock Reports - newser.com
Will Fulcrum Therapeutics Inc. continue its uptrendPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Signal strength of Fulcrum Therapeutics Inc. stock in tech scannersJuly 2025 Decliners & Fast Entry Momentum Alerts - newser.com
Fulcrum Therapeutics Inc. stock volume spike explainedMarket Risk Summary & Capital Protection Trade Alerts - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockMarket Trend Report & Fast Momentum Stock Entry Tips - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityMarket Movement Recap & Technical Entry and Exit Tips - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Statistical indicators supporting Fulcrum Therapeutics Inc.’s strengthSell Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.Market Activity Report & Reliable Volume Spike Alerts - newser.com
Will Fulcrum Therapeutics Inc. stock gain from strong economyMarket Activity Report & Fast Moving Trade Plans - newser.com
What is HC Wainwright's Estimate for FULC Q1 Earnings? - MarketBeat
How institutional buying supports Fulcrum Therapeutics Inc. stockJuly 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Price Target Raised to $7.00 - MarketBeat
Published on: 2025-10-31 05:47:11 - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - newser.com
Is Fulcrum Therapeutics Inc. trending in predictive chart modelsBreakout Watch & High Return Trade Guides - newser.com
How sustainable is Fulcrum Therapeutics Inc. stock dividend payoutMarket Volume Report & Accurate Intraday Trade Tips - newser.com
How to forecast Fulcrum Therapeutics Inc. trends using time series - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chart2025 Institutional Moves & Accurate Entry/Exit Alerts - newser.com
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights: Promising Advances in Sickle ... By GuruFocus - Investing.com Canada
Fulcrum Therapeutics Inc (FULC) Q3 2025 Earnings Call Highlights - GuruFocus
Fulcrum Therapeutics (FULC) Price Target Increased by 10.32% to 12.46 - MSN
RBC Capital Updates Fulcrum Therapeutics (FULC) Price Target Ami - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Piper Sandler Raises Price Target on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 1-Year HighShould You Buy? - MarketBeat
Fulcrum Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Fulcrum Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Fulcrum Therapeutics Narrows Loss And Gains Wall Street Praise - Finimize
Fulcrum Therapeutics, Inc. (FULC) Q3 FY2025 earnings call transcript - Yahoo Finance
FULC's PIONEER Trial Shows Promising Results for Sickle Cell Tre - GuruFocus
Fulcrum Therapeutics Inc. (FULC) Misses Q3 EPS by 2c - StreetInsider
Fulcrum Therapeutics' Q3 net loss narrows - MarketScreener
Fulcrum Therapeutics : Corporate PresentationOctober 2025 - MarketScreener
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):